Synthetic lethality is a phenomenon in which cancer cells containing mutations in certain pathways are hypersensitive to drugs that target related pathways. The two systems will jointly identify these targets and develop small-molecule therapies that are able to shut off specific epigenetic processes.
“Our platform identifies the unique activation mechanisms of molecular machines essential for cancer cell growth,” said Andreas Ladurner, PhD, chief scientific officer at Eisbach Bio. “With this insight, we are able to develop targeted drugs that selectively interfere with the ignition of the engines that tumor cells have come to rely upon. These drugs are safe and selective by design.”
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
